|
Thrombophilia and Adverse Maternal-
Perinatal
Outcomes
Caroline L. Stella, MD;
Labib M. Ghulmiyyah, MD;
Baha M. Sibai, MD
Should all women with
preeclampsia, abruptio placentae, IUGR, or fetal loss be screened?
And, if the results are positive, how should you proceed?
BONUS Coding Box on page 46
Nutraceuticals and Arthritis: Weighing the Evidence
Manita Singh, PharmD;
Nicole T. Ansani, PharmD;
Terence W. Starz, MD;
Molly T. Vogt, PhD
An evidence-based model provides the best approach to discussing CAM-care issues with patients.
Anxiety Disorders in Women, Part 1: Prevalence, Trends, and Psychotherapy
Tracey L. Skaer, BPharm, PharmD;
David A. Sclar, BPharm, PhD
Exploring gender-related incidence
and inclinations, the first part of this series sets
the stage for initial
diagnosis and treatment.
back
to top
Departments
Letter to the Editor
Editorial
The Practice of
Evidence-based Medicine
Dorothy Kammerer-Doak, MD
New Products
In the Pipeline
My Most
Memorable Moment
Murphy’s Laws of Obstetrics
E. Hakim-Elahi, MD
Case Report
Hereditary Thrombophilia and Thrombocythemia in Pregnancy
Gokhan Anil, MD, PGY-III;
Ziad A. Haidar, MD, PGY-IV;
Christos G. Hatjis, MD
What Your Patients
are Reading
Author Guidelines
CME Test
Patient Handout
What You Should Know
About Nutraceuticals
Folleto Informativo Para La Paciente
Lo que Usted debe Saber sobre los Nutracéuticos
Classified Advertisements
back
to top |
